Issue Ebook
cover story
Latest Issue
Volume 26 ， Issue 3 ， 2011
- Abstract：<正>Microglial activation plays an important role in a panel of neurological disorders such as multiple sclerosis（MS） and Parkinson’s disease（PD）,and is a key target for developing therapeutic strategies for these diseases.Ketogenic diet （KD）,which is able to inhibit microglial activation in substantia nigra pars compacta of mice,has been shown effective in a mouse model of PD,possibly through increasing D-β-hydroxybutyrate（D-β-HB）,a major component of ketone bodies.To verify this,we developed an in vitro model of microglia activation with a microglia line,BV-2,and investigated how D-β-HB have an effect on the LPS-stimulated BV-2 cells.We found D-β-HB is able to recover the cell viability,and inhibit the production of inflammatory mediators and cytokines such as ROS,nitrite,IL-1β,TNF-α,and IL-6,which otherwise were increased in LPS-stimulated BV-2 cells.We conclude that the LPS induced BV-2 cells activation is a valid in vitro model of microglia activation.D-β-HB is able to suppress the activation of BV-2 cells, which might account for one of the possible reasons of KD therapy on the PD model.0|22|1Updated：2026-03-12
- Abstract：<正>We present a rare case of primary chondrosarcoma of the liver in a 57-year-old man with pre-existing hepatitis B virus-related chronic hepatitis.The MRI scans showed a huge cystic-solid occupation of 18 cm×17 cm×11 cm in the right hepatic lobe.The tumor was completely resected,and the histological findings identified low-grade cartilaginous component with typical ring-and-arc chondroid matrix mineralization.Immunohistochemically,the neoplastic cells were positive for vimentin and S-100 protein.The patient received once postoperative adjuvant transcatheter arterial chemoembolization（TACE）at the 2nd month after discharge,and he is still alive for more than 13 months without recurrence and metastasis.To the best of our knowledge,this is the first case of primary chondrosarcoma of the liver.0|10|0Updated：2026-03-12
- Abstract：<正>Objective:To study the clinical characteristics and treatment of pulmonary embolism（PE）after transcatheter arterial chemoembolization（TACE）for hepatocellular carcinoma（HCC）.Methods:The clinical records of 13 512 patients diagnosed with HCC and received TACE from January 2000 to December 2009 were reviewed.Among these patients,5 031 were allocated into group A who had one or more disorders like diabetes,hypertension,coronary heart disease,obesity or varicose vein of lower limb,while the other 8 481 patients who did not have such disorders were in group B.Results:A total of 39 185 TACE procedures were performed for the 13 512 patients.Five（0.01%）patients in group A developed PE after TACE,of whom two recovered 4 and 5 d later with early anticoagulant therapy while the hypertension,coronary heart disease,obesity or varicose vein of lower limb are possibly more likely to develop PE other 3 died of respiratory failure within 5 h.The mortality of PE was 60%（3/5）.Conclusion:HCC patients with diabetes, after TACE than those without such disorders.Patients who have such disorders should be more carefully observed after TACE and early treatment with heparin should be applied once PE develops.0|12|1Updated：2026-03-12
- Abstract：<正>Objective The Patients with pelvic tumors were treated with tumor resection,hemi-pelvic allografting or artificial hemi-pelvic replacement for the improvement of their life quality.Methods Seven cases of pelvic tumor were treated with wide resection and hemi-pelvic allografting,and 35 cases with resection of pelvic tumors and artificial hemi-pelvic replacement.Results These 42 cases were all successfully operated upon without operative mortality.The results of long term following-up of 2.5 to 12 years（mean 5.4 years）showed that the increased and satisfactory functional recovery（50.0%）.Conclusion Hemi-pelvic allografting or artificial hemi-pelvic replacement after wide resection of pelvic tumors can improve the survival rate of patients,as well as reconstruction of the pelvis and the hip joint with satisfactory function.0|8|0Updated：2026-03-12
- Abstract：<正>Objective:To investigate the role of Hemocoagulase Injection used in the joint operation and the effect on the blood coagulable function.Methods:A total of 60 patients who undergoing joint operation in our hospital were randomly divided into two groups.Experiment group（Group A,n=30）was injected with 2 U Hemocoagulase Injection in 5 min before anesthesia induction.The contrast group（Group B,n=30）was treated with 0.9%normal saline in 5 min before anesthesia induction.Then common anesthesia was given to the two groups of patients.The venous blood was withdrawn for blood routine examination,thrombelastography and coagulable function at the time of pre-inducement, end of operation,and in 6 and 12 h after operation.The change of thrombelastograph and coagulable state were monitored during the whole surgery.And the volume of transfusion and hemorrhage between two groups was contrasted. Results:After the use of Hemocoagulase Injection,the operative time was shortened obviously（P<0.05）.The volumes hemorrhage and transfusion was obviously smaller in Group A than in Group B（P<0.01）.Hemocoagulase Injection did not influence fibrinogen and thrombelastograph of Group A（P>0.05）.Conclusion:Hemocoagulase Injection can reduce the volumes of hemorrhage and transfusion and not influence the coagulable function.It is worth using in the joint operation.0|14|1Updated：2026-03-12
- Abstract：<正>Background The epidemiological characteristics of drug-resistant tuberculosis（DR-TB）is fundamental to improving the prevention and control of DR-TB.Mutations in katG315 is thought to be the most predictive molecule markers for Isoniazid（INH）resistance in Mycobacterium tuberculosis（MTB）.However,mutations to these genes have not been thoroughly studied in China,and epidemiological evidence of their expression levels are especially lacking in the southwest of China,which has a high TB burden within the population.Methods MTB isolates were obtained from patients with active pulmonary tuberculosis at the TB dispensary and Chest hospital in Chongqing city between June 2003 and June 2006.Proportion methods were used to test the sensitivity to INH,RFP,SM and EMB of cultured MTB.A total of 100 MTB isolates were also randomly selected for analysis of the molecular mutation spectrum of katG by DNA sequencing.Results Totally 1 089 MTB isolates that completed positive sputum cultures and evaluated for their sensitivity to the four first-line drugs among 2 777 patients with TB.The prevalence of DR-TB and multi-drug resistant tuberculosis（MDR-TB）were 27.7%（302/1089）and 7.3%（79/1089）,respectively.The resistance to anti-TB drugs was found to be highest for SM（16·3%）and INH（14·0%）.There was also a significant increase in the prevalence of resistance to RFP and EMB（P<0.01）,and an increase in MDR-TB between June 2003 and June 2004 and between July 2005 and June 2006.The total mutation rate of katG315 was 75·5%（37/49）in INH-resistant MTB,and mutation sites included S315T,S315N and S315I with mutation rates of 81·1%（30/37）,13·5%（5/37）and 5·4%（2/37）,respectively. No katG315 mutants were found in any of the 48 INH-sensitive MTB.Our preliminary diagnostic results suggest that mutations in katG315 may potentially serve as molecular markers that can be used to diagnose the resistance to anti-TB drug of INH.Conclusion In the Chongqing,DR-TB and MDR-TB are increasing,and are becoming key problems for tuberculosis control.The use of katG315 mutations as potential molecule markers for drug resistance to INH may help improve patient treatment and decrease the spread of the disease.0|34|0Updated：2026-03-12
- Abstract：<正>Aortopuimonary window is a rare congenital cardiac malformation,which is previously repaired using cardiopulmonary bypass.However,some cases were reported to repair the aortopuimonary septal defect by transcatheter closure.Here we present a 30 year-old woman with a 7-mm aortopuimonary window,who was successfully treated using a modified double-disk PmVSD occluder.0|5|0Updated：2026-03-12
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
0